Skip to main content

and
Your search also matched 28 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Safe administration of rituximab for follicular lymphoma after obinutuzumab infusion-related reaction

Include preview-only content
  1. Article

    Open Access

    Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma

    Extranodal involvement predicts poor outcomes of diffuse large B cell lymphoma (DLBCL), but the impact of the metabolic tumor burden (MTV) of extranodal sites using positron emission tomography has not been cl...

    Kana Oiwa, Kei Fujita, Shin Lee, Tetsuji Morishita in Annals of Hematology (2023)

  2. Article

    Open Access

    A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma

    This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (...

    Nobuhiko Nakamura, Senji Kasahara, Junichi Kitagawa in Experimental Hematology & Oncology (2022)

  3. Article

    Open Access

    Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling

    Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) is a diagnosis of exclusion, being the most common entity in mature T-cell neoplasms, and its molecular pathogenesis remains significantly unders...

    Yosaku Watatani, Yasuharu Sato, Hiroaki Miyoshi, Kana Sakamoto, Kenji Nishida in Leukemia (2019)

  4. Article

    Open Access

    Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study

    Dasatinib has shown promising anti-leukemic activity against chronic myeloid leukemia (CML). However, patients receiving dasatinib frequently require dose reductions and treatment interruptions (treatment alte...

    Shuichi Mizuta, Masashi Sawa, Hisashi Tsurumi in International Journal of Clinical Oncology (2018)

  5. Article

    Open Access

    Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy

    We previously reported that oral ingestion of polaprezinc, a zinc-L-carnosine, suspended in sodium alginate solution prevents oral mucositis in patients receiving radiotherapy or high-dose chemotherapy. In the...

    Hiroko Hayashi, Ryo Kobayashi, Akio Suzuki, Yuto Yamada in Medical Oncology (2016)

  6. Article

    Open Access

    Synergistic growth inhibition by acyclic retinoid and phosphatidylinositol 3-kinase inhibitor in human hepatoma cells

    A malfunction of RXRα due to phosphorylation is associated with liver carcinogenesis, and acyclic retinoid (ACR), which targets RXRα, can prevent the development of hepatocellular carcinoma (HCC). Activation o...

    Atsushi Baba, Masahito Shimizu, Tomohiko Ohno, Yohei Shirakami, Masaya Kubota in BMC Cancer (2013)

  7. Article

    Open Access

    Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/dbobese mice

    Obesity and related metabolic abnormalities, including inflammation and lipid accumulation in the liver, play a role in liver carcinogenesis. Adipocytokine imbalances, such as decreased serum adiponectin level...

    Masahito Shimizu, Yoichi Yasuda, Hiroyasu Sakai, Masaya Kubota in BMC Cancer (2011)